Oncologie nieuws
- Neural network-derived multivariate index assay demonstrates effective clinical performance in longitudinal monitoring of ovarian cancer risk
- Epredia, NovaScan to ink distribution agreement for MarginScan to aid doctors to detect non?melanoma skin cancer
- Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcomas: Looking Forward to What Is Next
- Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
- Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes
- ECHO phase III trial of AstraZeneca's Calquence combination regimen demonstrates significant and clinically meaningful improvement in PFS in 1st─line mantle cell lymphoma
- Acalabrutinib Combo Promising as First-Line Tx for Mantle Cell Lymphoma
- <em>SOX4</em> induces cytoskeleton remodeling and promotes cell motility via N-WASP/ARP2/3 pathway in colorectal cancer cells
- AstraZeneca shares positive interim results from phase 3 lymphoma trial
- Nivolumab Achieves High ORR and Durable PFS in Patients with dMMR/MSI-H Recurrent Endometrial or Ovarian Cancer
- Merck's phase 3 KEYNOTE─811 trial of Keytruda in combo with trastuzumab and fluoropyrimidine─ and platinum─containing chemotherapy meets dual primary endpoint of OS in patients with HER2─positive advanced gastric or GEJ adenocarcin
- [Correspondence] Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial
- [Correspondence] Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial
- Gene signatures from tissue-resident T cells as a predictive tool for melanoma patients
- Emerging biomarkers and molecular targets for precision medicine in cervical cancer